Treatment of COPD exacerbations: Antibiotics

European Respiratory Review

Volumn 14, Issue 94, 2005, Pages 32-38

  Wilson, R ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Antibiotics; Chronic obstructive pulmonary disease; Exacerbation

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFUROXIME; CLARITHROMYCIN; GEMIFLOXACIN; MOXIFLOXACIN;

BACTERIAL INFECTION; BRONCHOSCOPY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOLOGY; INFLAMMATION; MORAXELLA CATARRHALIS; REVIEW; SEROLOGY; SPUTUM; STREPTOCOCCUS PNEUMONIAE;

EID: 24644488912     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09058180.05.00009404     Document Type: Review

References (47)

1. Wilson R. Bacteria, antibiotics and COPD. Eur Respir J 2001; 17: 995-1007.
2. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8: 1333-1338.
3. Wilson R, Dowling RB, Jackson AD. The biology of bacterial colonization and invasion of the respiratory mucosa. Eur Respir J 1996; 9: 1523-1530.
4. Fletcher C, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema. New York, Toronto, Oxford University Press, 1976.
5. Anthonison NR. The British hypothesis revisited. Eur Respir J 2004; 23: 657-658.
6. Murphy TF, Sethi S. Bacteria infection in chronic obstruction pulmonary disease. Am Rev Respir Dis 1992; 146: 1067-1083.
7. Vestbo J, Prescott E, Lange P, the Copenhagen City Heart Study Group. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996; 153: 1530-1535.
8. Kanner RE, Anthonisen NR, Connett JE for the Lung Health Study Research Group. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358-364.
9. Donaldson GC, Seemungal TAR, Bhomik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
10. Spencer S, Calverley PMA, Burge PS, et al. Health status deterioration in patients with COPD. Am J Respir Crit Care Med 2001; 163: 122-128.
11. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589-593.
12. Wilkinson TMA, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2003; 167: 1090-1095.
13. Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations. Thorax 2002; 57: 759-764.
14. Gump DW, Phillips CA, Forsyth BR, McIntosh K, Lamborn KR, Stouch WH. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976; 113: 465-474.
15. Sethi S, Evans N, Grant B, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471.
16. Obaji A, Sethi S. Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones? Drugs Aging 2001; 18: 1-11.
17. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD. Chest 2001; 117: 1638-1645.
18. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive airways disease: a study of stable and exacerbated patients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316-1320.
19. Monso E, Rosell AI, Boret G, et al. Risk factors of lower airway bacterial colonization in chronic bronchitis. Eur Respir J 1999; 13: 338-342.
20. Zalacain R, Sobradillo V, Amilibia J, et al. Predispoing factors to bacterial colonisation in chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 343-348.
21. Peta R, Marchesani F, Agostinelli C, et al. Airway microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis 1998; 53: 262-267.
22. Bresser P, van Alphen L, Habets FJM. Persiting Haemophilus influenzae strains induce lower levels of interleukin-6 and interleukin-8 in H292 lung epithelial cells than non-persisting strains. Eur Respir J 1997; 10: 2319-2326.
23. Soler N, Ewig S, Torres A, Filella A, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 1015-1022.
24. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 2004; 23: 685-691.
25. Bandi V, Jakubowycz M, Kinyon C, et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microbiol 2003; 37: 69-75.
26. Qiu Y, Zhu J, Bandi V, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 968-975.
27. Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976; 113: 465-473.
28. Calder MA, Schonell ME. Pneumococcal typing and the problem of endogenous or exogenous re-infection in chronch bronchitis. Lancet 1971; 1: 1156-1159.
29. McHardy VU, Inglis JM, Calder MA, et al. A study of infective and other factors in exacerbations of chronic bronchitis. Br J Dis Chest 1980; 74: 228-307.
30. Groeneveld K, van Alphen LV, Eijk PP, et al. Endogenous and exogenous re-infection of Haemophilus influenzae in patients with chronic obstructive pulmonary disease: the effect of antibiotic treatment on persistence. J Infect Dis 1990; 161: 512-517.
31. Fisher M, Akhtar AJ, Calder MA, et al. Pilot study of factors associated with exacerbations in chronic bronchitis. BMJ 1969; 4: 187-192.
32. Baigelman W, Chodosh S, Pizzuto D, et al. Quantitative sputum gram stains in chronic bronchial disease. Lung 1979; 156: 265-270.
33. Murphy T, Sethi S, Niederman M. The role of bacteria in exacerbations of COPD (a constructive view). Chest 2000; 118: 204-209.
34. Sethi S, Wrona C, Grant BJB, Murphy TF. Strain-specific immune response to Haemophuus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 448-453.
35. Sethi S, Brauer A, Lobbins P, Eschberger K, Murphy TF. Systemic and mucosal immune responses to Moraxella catarrhalis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: A208.
36. Sethi S, Wrona C, Murphy TF. Serum immune response to colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: A864.
37. White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680-685.
38. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Respir Crit Care Med 2000; 109: 288-295.
39. Dowling RB, Rayner CFJ, Rutman A, et al. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am J Respir Crit Care Med 1997; 155: 327-336.
40. Saint SK, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. J Am Med Assoc 1995; 273: 957-960.
41. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
42. Allegra F, Blasi B, de Bernardi R, Cosentini P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomised study. Pulm Pharmacol Ther 2001; 14: 149-155.
43. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with seven day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501-513.
44. Wilson R, Schentag JJ, Ball P, Mandell LA. Comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Therap 2002; 24: 639-652.
45. Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-964.
46. Wilson R. Outcome predictors in bronchitis. Chest 1995; 108: 53s-57s.
47. Balter MS, LaForge J, Low DE, Mandell L, Grossman RE. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003; 10: Suppl B, 3B-32B.